NATCO PHARMA Share Price Up by 7%; BSE HEALTHCARE Index Up 0.8%
March 8, 2021 10:16 AM

NATCO PHARMA share price has zoomed 7% and is presently trading at Rs 894.

Meanwhile, the BSE HEALTHCARE Index is at 21,369 (up 0.8%).

Among the top Gainers in the BSE HEALTHCARE Index today is NATCO PHARMA (up 6.7%).

ABBOTT INDIA (down 0.1%) and SYNGENE INTERNATIONAL (down 0.1%) are among the top losers today.

Over the last one year, NATCO PHARMA has moved up from Rs 616 to Rs 894, registering a gain of Rs 279 (up 44.3%).

On the other hand, the BSE HEALTHCARE has moved up from 14,080 to 21,369, registering a gain of 7,289 points (up 51.8%) during the last 12 months.

The top buzzing stocks among the BSE HEALTHCARE Index stocks during this same period were LAURUS LABS (up 321.2%), J.B.CHEMICALS (up 112.2%) and GRANULES INDIA (up 104.7%).

What About the Benchmark Indices?

The BSE Sensex is at 50,986 (up 1.1%).

The top gainers among the BSE Sensex stocks today are ONGC (up 5.5%), AXIS BANK (up 2.8%) and L&T (up 2.6%). Other gainers include RELIANCE IND. (up 2.3%) and NTPC (up 2.3%). The most traded stocks in the BSE Sensex are ONGC and SBI.

In the meantime, NSE Nifty is at 15,111 (up 1.0%). The top gainers in the NSE Nifty include GAIL (up 5.7%), ONGC (up 5.5%) and UPL (up 4.1%). Other gainers include AXIS BANK (up 2.9%) and IOC (up 2.8%) are among the top gainers in NSE Nifty.

Over the last 12 months, the BSE Sensex has moved up from 38,409 to 50,986, registering a gain of 12,577 points (up 32.66%).

NATCO PHARMA Financial Update...

NATCO PHARMA net profit stood at Rs 1 billion for the quarter ended June 2020, compared to a profit of Rs 1 billion a year ago. Net Sales rose 16.8% to Rs 5.6 billion during the period as against Rs 4.8 billion in April-June 2019.

For the year ended March 2019, NATCO PHARMA reported 7.6% decrease in net profit to Rs 6.4 billion compared to net profit of Rs 7.0 billion during FY18.

Revenue of the company grew 4.9% to Rs 21 billion during FY19.

The current Price to earnings ratio of NATCO PHARMA, based on rolling 12 month earnings, stands at 7.4x.